Funding for the Cancer Research UK Manchester Institute

The total funding of the Cancer Research UK Manchester Institute for 2015 was £25m. The major source of this funding was awarded by Cancer Research UK (CRUK) via a core grant of £11.3m plus additional strategic funding of £5.4m. This funding enables the various scientific groups and service units within the Institute to carry out their research. 




The infrastructure of the CRUK Manchester Institute is funded by HEFCE generated income at a cost of £2.3m.

The balance of the Institute’s funding is received from a number of additional sources.  The research carried out through these additional projects enhances and supports the research undertaken by the core funding.

These sources are as follows:

  • AstraZeneca
  • Biotechnology and Biological Sciences Research Council
  • Bloodwise
  • British Lung Foundation
  • Christie Hospital NHS Foundation Trust
  • Clearbridge Biomedicals
  • European Commission
  • John Swallow Fellowship
  • Kay Kendall Leukaemia Fund
  • Lung Cancer Research Foundation
  • Medical Research Council
  • Menarini Biomarkers Singapore
  • Moulton Charitable Trust
  • Pancreatic Cancer Research Fund
  • Parsortix
  • Prostate Cancer UK
  • Roy Castle Lung Cancer Foundation
  • Wellcome Trust
  • Worldwide Cancer Research

We are immensely grateful to all our sponsors.